louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06201468: Frozen Shoulder (Scapular Mobilization Versus Scapular PNF)
Official title: SCAPULAR MOBILIZATION VERSUS SCAPULAR PROPRIOCEPTIVE NEURO MUSCULAR FACILITATION ON FROZEN SHOUDER
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Frozen Shoulder
Scapular Mobilization
Scapular Proprioceptive Neuromuscular Facilitation
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-01-11
Enrollment: 42
Sex: ALL
Minimum age (years): 40
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Two treatment groups will receive interventions as follows:

Group A (n = 21): will receive scapular mobilization combined with mobilization with movement (MWM) and capsular stretch for 4 weeks.

Group B (n = 21): will receive scapular proprioceptive neuromuscular facilitation combined with (MWM) and capsular stretch for 4 weeks.
Primary purpose: TREATMENT

Brief summary: This study will be conducted to examine and compare the effects of SM versus SPNF on shoulder pain, ROM and functional disabilities in patients with frozen shoulder.

Detailed description: This study will be conducted to examine and compare the effects of SM versus SPNF on shoulder pain, ROM and functional disabilities in patients with frozen shoulder.

Eligibility criteria: Inclusion Criteria:

- All the patients refferd from orthopaedic surgeon with diagnosis of adhesive capsulitis. Patients will be included in this study if they fulfil the following criteria

1. Case diagnosed with adhesive capsulitis, both primary and secondary.
2. Both males and females of the age group 40 to 60 years.
3. Limited active and passive movement of the shoulder joint movements, as well as difficulties with ADLs.

4- The onset of symptoms between 3 to 12 months. 5. Unilateral adhesive capsulitis.

Exclusion Criteria:

* 1. History of shoulder surgery or manipulation under anaesthesia, local corticosteroid injection administration to the affected shoulder within the last 6 months, 2. Neurological deficit affecting the shoulder function during daily activities, 3. Pathology of the shoulder joint other than adhesive capsulitis including rotator cuff tear, tendonitis at the shoulder and neck region, malignancies, history of trauma or accidental injuries of the upper limb.

  4- Other pathological conditions including, a history of stroke, history of mastectomy and coronary artery bypass grafting (CABG).

  5. Rheumatoid arthritis, osteoporosis, or disorders of the cervical spine, elbow, wrist or hand.

Primary outcomes:
measure: Shoulder disability
timeFrame: 4 weeks
measure: Shoulder range of motion
timeFrame: 4 weeks
Secondary outcomes:
measure: Scapular upward rotation
timeFrame: 4 weeks
measure: Lateral scapular slide test
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Cairo University
Study officials:
affiliation: Cairo University
name: Mona M ibrahim
role: STUDY_DIRECTOR
affiliation: Cairo University
name: mahmoud alsehemy
role: STUDY_DIRECTOR
References:
Clinical trial NCT02385968: Detection of Bacteria in Herniated Nucleus Material in Lumbar Disc Herniations by Culture and PCR
Official title: Detection of Bacteria in Herniated Nucleus Material in Lumbar Disc Herniations by Culture and PCR
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Lumbar Disc Herniations
Keywords: Modic
Microbiology
Immunology
Lead sponsor: Spine Centre of Southern Denmark
Sponsor class: OTHER
Collaborators: name: Vejle Hospital
First posted: 2015-03-11
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patient with MRI-confirmed lumbar disc herniation. Lumbar disc herniation. Age between 18 and 65 years. No prior spine surgery. No diagnosed dementia.

Brief summary: The aim is to investigate if herniated nucleus material in lumbar disc herniations is infected with bacteria, and if so, to determine their prevalence (control group), and to determine if patients with pre-existing Modic changes type 1 have a higher incidence of bacterial growth in relevant lumbar disc samples than patients without Modic changes.

A cohort of 15 patients with pre-existing Modic and 15 without-undergoing primary surgery will be examined.

Detailed description: The nucleus material will be evacuated and divided into 5 biopsies, each with a new set of sterile instruments and placed in separate sterile glass vials with one drop of sterile saline to prevent drying of biopsy.

The primary outcome, i.e., bacterial growth on a per-patient basis. Bacterial growth shall be detected in minimum 3 out of 5 biopsies for the patient to be scored as positive for bacteria.

Eligibility criteria: Inclusion Criteria:

* MRI-confirmed lumbar disc herniation.
* Age between 18 and 65 years.
* No prior spine surgery.
* No diagnosed dementia.

Exclusion Criteria:

* Antibiotic treatment within the previous two weeks.
* History of alcohol abuse, illicit drug use or drug abuse, or significant mental illness
* Known immune deficiency state (e.g., positive for human immunodeficiency virus) or in treatment with immunosuppressive drugs including high dose steroids or cyclosporine.
* Concurrent infections (infections of skin, urinary tract infection, other skin diseases, e.g. Acne vulgaris).
* Previous epidural instrumentation.
* Uncontrolled, unstable or recently diagnosed autoimmune disease, including but not limited to systemic lupus erythematosus, inflammatory bowel disease, sarcoidosis, rheumatoid arthritis, or psoriasis.

Primary outcomes:
measure: Bacterial growth on a per-patient basis
timeFrame: at time of surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Middelfart
country: Denmark
facility: Middelfart Spinesurgery research department
state: Region Of Southern Denmark
Study officials:
affiliation: Sygehus Lillebaelt
name: Karen H. Hansen
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02183168: Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis
Official title: A Randomized, Open Label, 3-arm Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Spondylitis, Ankylosing
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2014-07-08
Enrollment: 192
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Study to assess the efficacy and safety of meloxicam suppository 15 mg once daily, meloxicam tablet 15 mg once daily compared with Indomethacin suppository (50 mg daily) in patients with ankylosing spondylitis


Eligibility criteria: Inclusion Criteria:

* Active ankylosing spondylitis (pain rated \>= 40 mm on a VAS and increased of at least 30% after nonsteroidal anti-inflammatory drugs (NSAIDs) wash-out)), without peripheral arthritis and inflammatory bowel disease

Exclusion Criteria:

* none

Primary outcomes:
measure: Overall pain during the previous 48 hours assessed on a Visual Analogue Scale (VAS)
timeFrame: 6 weeks
measure: Functional Index of ankylosing spondylitis of Dougados
timeFrame: 6 weeks
measure: Overall assessment of disease activity by the patient on VAS
timeFrame: 6 weeks
Secondary outcomes:
measure: Overall assessment of disease activity by the investigator on a VAS
timeFrame: 6 weeks
measure: Global efficacy assessed by the patient (verbal rating scale)
timeFrame: 6 weeks
measure: Global efficacy assessed by the investigator (verbal rating scale)
timeFrame: 6 weeks
measure: Duration of morning stiffness
timeFrame: 6 weeks
measure: Evaluation of spinal pain by the investigator (verbal rating scale)
timeFrame: 6 weeks
measure: Assessment of Schober test
timeFrame: 6 weeks
measure: Assessment of Chest expansion
timeFrame: 6 weeks
measure: Assessment of Fingers - to - floor test
timeFrame: 6 weeks
measure: Assessment of Night pain (verbal rating scale)
timeFrame: 6 weeks
measure: Total number of study withdrawals
timeFrame: 6 weeks
measure: Number of study withdrawals due to lack of efficacy
timeFrame: 6 weeks
measure: Assessment of Paracetamol consumption
timeFrame: 6 weeks
measure: Assessment of Patient status with regard to disease condition
timeFrame: 6 weeks
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06750068: Evaluation of 3D-printed Space Maintainers Versus Conventional Space Maintainer : a Randomized Clinical Trial
Official title: Clinical Evaluation of Digitally Fabricated 3D-printed Band and Loop Space Maintainers Versus Conventional Band and Loop Space Maintainer : a Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Tooth Loss
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-12-27
Enrollment: 50
Sex: ALL
Minimum age (years): 4
Maximum age (years): 8
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: 3D printed band and loop space maintainer Conventions band and loop space maintainer
Primary purpose: OTHER

Brief summary: This study aims to compare the clinical evaluation and patients' satisfaction of space maintainers produced by digital workflow using the 3D-printing method (3D-SMs) versus conventional band and loop space maintainers (C-SMs) produced by traditional methods.


Eligibility criteria: Inclusion Criteria:

* Lower first permanent molar in active state of eruption
* Patient and parent showing cooperation and compliance.
* Medically free children.
* According to space analysis available space is less than or equal to needed space
* Primary molar loss in the last 1 week due to caries, infection, and resorption (to eliminate possible space loss)
* Caries free, non-restored buccal surfaces of the mandibular second primary molars and deciduous canines.

Exclusion Criteria:

* Children with previous allergies to stainless steel.
* There was less than one year left for the permanent tooth to erupt (to prevent possible abutment toot loss)
* The patient's oral hygiene is not sufficient and has periodontal problems (to accurately assess the periodontal effects)

Primary outcomes:
measure: Survival rate
timeFrame: 1 year
Secondary outcomes:
measure: Gingival health of the abutment
timeFrame: 0,6,12 months
measure: Plaque accumulation on the abutment tooth
timeFrame: 0,6,12 months
measure: Patients' satisfaction about the impression technique
timeFrame: Immediately after the im- pression/scanning
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02669368: Magnesium Sulfate Effects on Onset and Duration of Low Dose Rocuronium in Patients Undergoing Laparoscopic Cholecystectomy
Official title: Effects of Magnesium Sulfate on Onset and Duration of Low Dose Rocuronium in Patients Undergoing Laparoscopic Cholecystectomy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Muscle Relaxation
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2016-02-01
Enrollment: 75
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to evaluate effects of magnesium sulfate on onset and duration of low dose rocuronium, intubation condition and surgical condition in patients undergoing laparoscopic cholecystectomy.


Eligibility criteria: Inclusion Criteria:

* American Society of Anesthesiologists physical status 1 or 2.
* BMI of 25-34.9 kg/m2.
* Patients scheduled for laparoscopic cholecystectomy.

Exclusion Criteria:

* Severe respiratory or cardiac disease.
* Hepatic or renal function impairment.
* Neuromuscular disease.
* Patients on medications affecting neuromuscular function.
* Patients with known allergy to the drugs.

Primary outcomes:
measure: The time of onset the action of Rocuronium
timeFrame: Time from injection of Rocuronium till T1 suppression more than 95% up to 10 minutes.
measure: The time at which Maximal suppression
timeFrame: Time from the injection of Rocuronium to T1 maximal suppression time (TOF=0) up to an hour.
measure: Reversal of Rocuronium
timeFrame: Time from injection of Rocuronium till reversal of T1 (TOF=25%) around an hour after induction of anesthesia
Secondary outcomes:
measure: Intubation condition
timeFrame: Within 10 minutes after induction of anesthesia
measure: Surgical condition
timeFrame: During surgery
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Assiut University Hospitals
Study officials:
affiliation: Assiut University
name: Nawal Abdelaziz Gadelrab, Professor
role: STUDY_CHAIR
affiliation: Assiut University Hospitals
name: Ola Mahmoud Wahba, Lecturer
role: STUDY_DIRECTOR
affiliation: Assiut University Hospitals
name: Ahmed Hamada Hamed Amin, Resident
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05807568: MIStreatment Screening in Elders Before Discharge
Official title: MIStreatment Screening in Elders Before Discharge (MISSED) Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Elder Abuse
Surveys and Questionnaires
Self Neglect
Geriatrics
Geriatric Assessment
Health Services for the Aged
Aged
Keywords: Elder Mistreatment
Abuse
Neglect
Exploitation
Screening
Geriatric
Questionnaire
Lead sponsor: The University of Texas Health Science Center, Houston
Sponsor class: OTHER
First posted: 2023-04-11
Enrollment: 100
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The purpose of this study is to demonstrate the feasibility of introducing, implementing, and integrating a brief, existent elder mistreatment screening tool (the National Collaboratory to Address Elder Mistreatment (NCAEM)'s Elder Mistreatment - Screening And Response Tool (EM-SART) Pre-Screen) in the Memorial Herman Hospital (MHH)-Texas Medical Center (TMC)Acute Care of Elders(ACE) (MHH-TMC ACE) unit and to identify older adults who may already be suffering from abuse, neglect, and/or financial exploitation, as well as connecting the study participants to the primary Geriatric Medicine team on the ACE unit such that additional care, evaluation (including additional in-depth mistreatment screening), and intervention can be taken to prevent and minimize further harm prior to discharge. The investigators hope to reduce missed opportunities for mistreatment detection to lead to safer health outcomes and hospital discharges.


Eligibility criteria: Inclusion Criteria:

* current admission to the MHH-TMC ACE unit
* ability to independently hear, understand, and verbally answer the 3 participant questions on the NCAEM's EM-SART Pre-Screen screening tool when it is read to them

Exclusion Criteria:

* unwillingness to participate in the research study.

Primary outcomes:
measure: Number of units using this NCAEM EM-SART Pre-Screen tool
timeFrame: 12 months after study
measure: Number of participants who have identified elder mistreatment
timeFrame: 15 minute evaluation of each participant, no follow-up
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: The University of Texas Health Science Center at Houston
state: Texas
Study officials:
affiliation: The University of Texas Health Science Center, Houston
name: Julia A Hiner, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06955468: Evaluating a Bidirectional Priming Intervention for Goals-of-care Communication in Oncology
Official title: Development of a Bidirectional Priming Intervention for Goals-of-care Communication in Oncology
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Lung Cancers
Gastrointestinal Cancers
Keywords: Communication
Lead sponsor: Abramson Cancer Center at Penn Medicine
Sponsor class: OTHER
Collaborators: name: Conquer Cancer Foundation
First posted: 2025-05-02
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This pilot study will evaluate whether an intervention aimed at hospitalized patients with advanced lung and gastrointestinal cancers can help facilitate goals-of-care (GOC) communication with their oncologists after discharge.

While GOC communication is a recommended component of routine oncology care, many patients with solid cancers do not have the opportunity to talk with their oncologist about their goals and end-of-life preferences. Prior research has shown that a systematic method of prompting GOC communication with at-risk patients would address a key barrier to timely GOC communication and ensure that patients receive care that is in line with their personal preferences.

This trial will enroll 80 participants, who will be randomized 1:1 to either an intervention or a control group. Participants in the intervention group will complete a short survey regarding their goals, preferences, and disease understanding. Survey responses will be shared with each participant's outpatient oncology team. Oncologists will subsequently receive a nudge in the electronic medical record reminding them of key survey responses and encouraging them to discuss them at the patient's first clinic visit after hospital discharge.

The primary feasibility outcome is intervention completion rate and the primary clinical outcome is GOC documentation within 30 days of discharge in the intervention group compared to the control group.


Eligibility criteria: Inclusion Criteria:

1. Unplanned admission to the HUP Solid Oncology service;
2. Underlying diagnosis of advanced lung or GI cancer, defined as metastatic or locally advanced disease;
3. Anticipated discharge within the next 72h; and
4. Primary oncologist is based at HUP; or
5. Family member/caregiver of a patient meeting the above 4 criteria.

Exclusion Criteria:

1. Unable to complete survey in English.

Primary outcomes:
measure: Intervention Completion Rate
timeFrame: From enrollment to 30 days after hospital discharge
measure: GOC Documentation
timeFrame: From enrollment to 30 days after hospital discharge
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Hospital of the University of Pennsylvania
state: Pennsylvania
Study officials:
References:
Clinical trial NCT01104168: Diabetes in the Elderly: Retrospective Study
Official title: Diabetes Care in Nursing Home Residents
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes
Keywords: diabetes
elderly
nursing home resident
Lead sponsor: Emory University
Sponsor class: OTHER
Collaborators: name: Sanofi
First posted: 2010-04-15
Enrollment: 1409
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: older adults ages 65+ admitted to two large long-term care facilities

Brief summary: Diabetes is highly prevalent in the elderly, afflicting about 20% of older adults aged 65-75 years and 40% of adults \>80years of age. Management of hyperglycemia is challenging in the geriatric population in long-term facilities. Numerous factors place hospitalized patients at increased risk for hyperglycemia including aging, sedentary life, stress of medical and surgical comorbidities, and changes in antidiabetic regimen. In addition, elderly patients often experience changes in their nutritional intake and organ dysfunction which increase the risk of hypoglycemic events.

There are only a few retrospective studies in elderly patients analyzing quality of diabetes care and glycemic control adjusted for medications and presence of co-morbidities in long-term care facilities. In addition, no randomized controlled trials have demonstrated benefits of glycemic control on clinical outcome, quality of life, and rate of acute metabolic complications (hyperglycemia and hypoglycemic events) in long-term care facilities.

Detailed description: The investigators will conduct a retrospective study to determine the prevalence of diabetes, comprehensively describe the management of diabetes, and to evaluate the impact of quality of care and glycemic control on clinical outcome in elderly subjects admitted to two large long-term care facilities: Grady Health System (GHS) and Veterans Administration Medical Center (VAMC) in Atlanta, Georgia between 1/01/08 to 12/31/08.

Eligibility criteria: Inclusion Criteria:

* ages 65+
* diagnosis of diabetes

Primary outcomes:
measure: prevalence of diabetes
timeFrame: 1 year
Secondary outcomes:
measure: differences in glycemic control
timeFrame: 1 year
measure: evaluate the impact of quality of care and glycemic control on clinical outcome in elderly subjects
timeFrame: 1 year
Other outcomes:
Locations:
city: Atlanta
country: United States
facility: A.G. Rhodes Homes
state: Georgia
city: Atlanta
country: United States
facility: Bud Terrace Homes
state: Georgia
Study officials:
affiliation: Emory University
name: Guillermo Umpierrez, MD
role: PRINCIPAL_INVESTIGATOR
References: